IP Library Granted Patent US 10,415,043
Granted Patent B2
US 10,415,043 · App. 15/285,179 · Granted Sep 17, 2019

Vitamin prototrophy as a selectable marker

Inventors: Michael Koepke (Skokie, IL); Bakir Al-Sinawi (Sydney, AU)
Assignee: LANZATECH NEW ZEALAND LIMITED
C12N15/65C12N1/20C12N9/1014C12N9/88C12N15/52C12N15/74C12Y201/02011C12Y401/01011C12Y401/99017C12N9/93C12Y202/01011C12Y603/02001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,415,043
App. No.
15/285,179
Granted
Sep 17, 2019
Kind
B2
Abstract

One or more genes in a biosynthesis pathway for a vitamin or other essential nutrient which is needed for the survival of a microorganism can be used as an effective selective marker to identify cells transformed with an exogenous nucleic acid. The microorganism does not naturally contain or express the one or more gene. This permits genetic manipulations to be performed. It permits lower cost fermentations to be performed. It permits production of the essential nutrient for subsequent commodity use.

Claims (12)

1. A method of using vitamin prototrophy as a selectable marker comprising:

(a) transforming a microorganism auxotrophic for a vitamin with both a vitamin biosynthesis gene and a gene conferring a desired property, wherein the microorganism is not transformed with an antibiotic resistance gene and

(b) culturing the microorganism in the absence of the vitamin,

wherein growth of the microorganism in the absence of the vitamin indicates successful transformation of the microorganism with both the vitamin biosynthesis gene and the gene conferring a desired property,

wherein the vitamin is thiamine, the vitamin biosynthesis gene encodes thiamine biosynthesis protein (ThiC) (EC 4.1.99.17) derived from Clostridium ragsdalei , and the microorganism is Clostridium autoethanogenum.

2. The method of claim 1 , wherein the culturing is performed in the absence of an antibiotic.

3. The method of claim 1 , wherein antibiotic resistance is not used as a selectable marker.

4. The method of claim 1 , wherein transformation with the vitamin biosynthesis gene renders the microorganism prototrophic for the vitamin.

5. The method of claim 1 , wherein the gene conferring the desired property is not an antibiotic resistance gene, an auxotrophic marker, or a reporter gene.

6. The method of claim 1 , wherein the microorganism is further transformed with a second vitamin biosynthesis gene encoding methyl-2-oxobutanoate hydroxymethyltransferase (PanB) (EC 2.1.2.11), pantoate-beta-alanine ligase (PanC) (EC 6.3.2.1), and aspartate 1-decarboxylase (PanD) (EC 4.1.1.11).

7. The method of claim 6 , wherein the second vitamin biosynthesis gene is panBCD derived from Clostridium beijerinckii.

8. The method of claim 1 , wherein the method is used to select against an undesirable or contaminating microorganism that is auxotrophic for the vitamin.

Assignments (1)
RELEASE OF SECURITY INTEREST Recorded May 9, 2022
From: VENTURE LENDING & LEASING VII, INC.; VENTURE LENDING & LEASING VIII, INC.
To: LANZATECH NEW ZEALAND LIMITED; LANZATECH, INC.; LANZATECH FREEDOM PINES BIOREFINERY LLC; LANZATECH HONG KONG LIMITED; LANZATECH PRIVATE LIMITED; LANZATECH UK LIMITED
Reel/Frame 059910/0789 →
Continuity (3)
Continuation 13900172 · May 22, 2013
Provisional Application 61650757 · May 23, 2012
Related Publication 20170016007A1 · Jan 19, 2017